SCHEDULE 13G/A: StemPoint Capital LP and Affiliates Disclose 8.2% Stake in Vistagen Therapeutics
Beneficial Ownership Disclosure
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly disclosed a beneficial ownership of 8.2% in Vistagen Therapeutics, Inc., as of December 31, 2024.
Summary
- StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G, disclosing their beneficial ownership in Vistagen Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 2,328,492 shares of Vistagen Therapeutics' Common Stock.
- This aggregate amount represents 8.2% of the outstanding Common Stock of Vistagen Therapeutics.
- The beneficial ownership consists of 1,711,743 shares and 616,749 shares issuable upon the exercise of warrants.
- The percentage of class is calculated based on 27,843,466 shares outstanding as of November 6, 2024, as reported in the Issuer's Form 10-Q, plus the shares the Reporting Persons have the right to acquire upon warrant exercise.
- The Reporting Persons hold shared voting power over 2,053,842 shares and shared dispositive power over 2,328,492 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook. It is a neutral, compliance-driven filing.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment entity in a publicly traded biotechnology company. Such disclosures provide transparency regarding significant shareholder stakes, which can be relevant for understanding institutional interest and potential influence in the company.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception and liquidity.
- Management: Awareness of a substantial shareholder group that may engage with the company on strategic matters, though the filing states the stake is not for influencing control.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which 27,843,466 shares of Vistagen Therapeutics were reported outstanding in the Issuer's Form 10-Q. |
| 2024-11-07 | Date Vistagen Therapeutics' quarterly report on Form 10-Q for the period ended September 30, 2024, was filed with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G Amendment No. 1. |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Vistagen Therapeutics, StemPoint Capital, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, SEC Filing, Institutional Ownership, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.